Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology

The aims of this study were to define the risk of serious bacterial infections in patients receiving specific biological disease-modifying anti-rheumatic drugs (bDMARDs) and evaluating the effect of concomitant synthetic DMARDs (sDMARDs) in a large population-based sample of rheumatoid arthritis (RA...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental rheumatology 2019-01, Vol.37 (1), p.60-66
Hauptverfasser: Carrara, Greta, Bortoluzzi, Alessandra, Sakellariou, Garifallia, Silvagni, Ettore, Zanetti, Anna, Govoni, Marcello, Scirè, Carlo Alberto
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 66
container_issue 1
container_start_page 60
container_title Clinical and experimental rheumatology
container_volume 37
creator Carrara, Greta
Bortoluzzi, Alessandra
Sakellariou, Garifallia
Silvagni, Ettore
Zanetti, Anna
Govoni, Marcello
Scirè, Carlo Alberto
description The aims of this study were to define the risk of serious bacterial infections in patients receiving specific biological disease-modifying anti-rheumatic drugs (bDMARDs) and evaluating the effect of concomitant synthetic DMARDs (sDMARDs) in a large population-based sample of rheumatoid arthritis (RA) deriving from an administrative health database. Data were extracted from health databases of Lombardy Region, Italy (2004-2013), as a part of the RECord-linkage On Rheumatic Diseases (RECORD) study. Patients with RA treated with approved bDMARDs were included. Hospitalisations for bacterial infections were evaluated by hospital discharge forms. The association between drug exposure and infections was assessed by survival models, with time-dependent covariates. Results are presented as hazard ratios (HR) and 95%CI, crude and adjusted for pre-specified confounders (sex, age, disease duration, Charlson Comorbidity Index, previous biologics, previous infections, use of methotrexate, leflunomide, corticosteroids, non-steroidal anti-inflammatory drugs). 4,656 RA patients with at least one bDMARD prescription were included, for a total of 7,601 biological courses; 3,603 (77.4%) women with a mean (SD) age of 55.8 (12.7) years. Crude incidence rate of hospitalised infection ranged from 0.14 to 2.95 per 1000 person-years. After multivariable adjustment, abatacept users (HR 0.29, 95%CI 0.10-0.82) had significantly lower risk of infections compared to etanercept. Concurrent treatment with methotrexate (0.72, 0.52-0.99) reduced the overall risk of infection while glucocorticoids increased it (1.09 per mg/day, 1.06-1.11). In RA patients treated with bDMARDs, abatacept was associated with the lowest risk of infections; overall risk was mitigated by concomitant methotrexate and increased by glucocorticoids in a dose-dependent manner.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2094422177</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2094422177</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-9ad1f88e58d0de991e8f2cc0f2533153f7992c721a8a204a02b6b411903b6c1a3</originalsourceid><addsrcrecordid>eNo1kc9u1EAMxnMA0dLyCsjHXhbNTP4fq6VApUqVFipxWzkTT-M2yYTxRCivytOQsMvJn-SfP3-y3ySXKq3NrsqLnxfJe5EXpUyRF-W75CJVOquyTF0mfw4sr-AddF4mjtizYGQ_gvMBhAL7WaBBG1eJPfDoyG59WSVMK0pjFPjNsYPQ0Txg9NwChtgFjiwQA2Gk9kQ07Hv_zFY-we2I_SIr4IIfIHYEh7u9Dy30PL7iM8HjCIeTIVv4zEIoBBLndtnSbgP3W1oc4bu3THH5l_g8sq1ZrpO3DnuhD-d6lTx9ufux_7Z7ePx6v7992E1G67irsdWuqiivWtVSXWuqnLFWOZOnqc5TV9a1saXRWKFRGSrTFE2mda3SprAa06vk5uQ7Bf9rJonHgcVS3-NI6_WORtVZZowuyxX9eEbnZqD2OAUeMCzH__9I_wLzzIvU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2094422177</pqid></control><display><type>article</type><title>Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology</title><source>Alma/SFX Local Collection</source><creator>Carrara, Greta ; Bortoluzzi, Alessandra ; Sakellariou, Garifallia ; Silvagni, Ettore ; Zanetti, Anna ; Govoni, Marcello ; Scirè, Carlo Alberto</creator><creatorcontrib>Carrara, Greta ; Bortoluzzi, Alessandra ; Sakellariou, Garifallia ; Silvagni, Ettore ; Zanetti, Anna ; Govoni, Marcello ; Scirè, Carlo Alberto</creatorcontrib><description>The aims of this study were to define the risk of serious bacterial infections in patients receiving specific biological disease-modifying anti-rheumatic drugs (bDMARDs) and evaluating the effect of concomitant synthetic DMARDs (sDMARDs) in a large population-based sample of rheumatoid arthritis (RA) deriving from an administrative health database. Data were extracted from health databases of Lombardy Region, Italy (2004-2013), as a part of the RECord-linkage On Rheumatic Diseases (RECORD) study. Patients with RA treated with approved bDMARDs were included. Hospitalisations for bacterial infections were evaluated by hospital discharge forms. The association between drug exposure and infections was assessed by survival models, with time-dependent covariates. Results are presented as hazard ratios (HR) and 95%CI, crude and adjusted for pre-specified confounders (sex, age, disease duration, Charlson Comorbidity Index, previous biologics, previous infections, use of methotrexate, leflunomide, corticosteroids, non-steroidal anti-inflammatory drugs). 4,656 RA patients with at least one bDMARD prescription were included, for a total of 7,601 biological courses; 3,603 (77.4%) women with a mean (SD) age of 55.8 (12.7) years. Crude incidence rate of hospitalised infection ranged from 0.14 to 2.95 per 1000 person-years. After multivariable adjustment, abatacept users (HR 0.29, 95%CI 0.10-0.82) had significantly lower risk of infections compared to etanercept. Concurrent treatment with methotrexate (0.72, 0.52-0.99) reduced the overall risk of infection while glucocorticoids increased it (1.09 per mg/day, 1.06-1.11). In RA patients treated with bDMARDs, abatacept was associated with the lowest risk of infections; overall risk was mitigated by concomitant methotrexate and increased by glucocorticoids in a dose-dependent manner.</description><identifier>ISSN: 0392-856X</identifier><identifier>PMID: 30148440</identifier><language>eng</language><publisher>Italy</publisher><ispartof>Clinical and experimental rheumatology, 2019-01, Vol.37 (1), p.60-66</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30148440$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carrara, Greta</creatorcontrib><creatorcontrib>Bortoluzzi, Alessandra</creatorcontrib><creatorcontrib>Sakellariou, Garifallia</creatorcontrib><creatorcontrib>Silvagni, Ettore</creatorcontrib><creatorcontrib>Zanetti, Anna</creatorcontrib><creatorcontrib>Govoni, Marcello</creatorcontrib><creatorcontrib>Scirè, Carlo Alberto</creatorcontrib><title>Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>The aims of this study were to define the risk of serious bacterial infections in patients receiving specific biological disease-modifying anti-rheumatic drugs (bDMARDs) and evaluating the effect of concomitant synthetic DMARDs (sDMARDs) in a large population-based sample of rheumatoid arthritis (RA) deriving from an administrative health database. Data were extracted from health databases of Lombardy Region, Italy (2004-2013), as a part of the RECord-linkage On Rheumatic Diseases (RECORD) study. Patients with RA treated with approved bDMARDs were included. Hospitalisations for bacterial infections were evaluated by hospital discharge forms. The association between drug exposure and infections was assessed by survival models, with time-dependent covariates. Results are presented as hazard ratios (HR) and 95%CI, crude and adjusted for pre-specified confounders (sex, age, disease duration, Charlson Comorbidity Index, previous biologics, previous infections, use of methotrexate, leflunomide, corticosteroids, non-steroidal anti-inflammatory drugs). 4,656 RA patients with at least one bDMARD prescription were included, for a total of 7,601 biological courses; 3,603 (77.4%) women with a mean (SD) age of 55.8 (12.7) years. Crude incidence rate of hospitalised infection ranged from 0.14 to 2.95 per 1000 person-years. After multivariable adjustment, abatacept users (HR 0.29, 95%CI 0.10-0.82) had significantly lower risk of infections compared to etanercept. Concurrent treatment with methotrexate (0.72, 0.52-0.99) reduced the overall risk of infection while glucocorticoids increased it (1.09 per mg/day, 1.06-1.11). In RA patients treated with bDMARDs, abatacept was associated with the lowest risk of infections; overall risk was mitigated by concomitant methotrexate and increased by glucocorticoids in a dose-dependent manner.</description><issn>0392-856X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNo1kc9u1EAMxnMA0dLyCsjHXhbNTP4fq6VApUqVFipxWzkTT-M2yYTxRCivytOQsMvJn-SfP3-y3ySXKq3NrsqLnxfJe5EXpUyRF-W75CJVOquyTF0mfw4sr-AddF4mjtizYGQ_gvMBhAL7WaBBG1eJPfDoyG59WSVMK0pjFPjNsYPQ0Txg9NwChtgFjiwQA2Gk9kQ07Hv_zFY-we2I_SIr4IIfIHYEh7u9Dy30PL7iM8HjCIeTIVv4zEIoBBLndtnSbgP3W1oc4bu3THH5l_g8sq1ZrpO3DnuhD-d6lTx9ufux_7Z7ePx6v7992E1G67irsdWuqiivWtVSXWuqnLFWOZOnqc5TV9a1saXRWKFRGSrTFE2mda3SprAa06vk5uQ7Bf9rJonHgcVS3-NI6_WORtVZZowuyxX9eEbnZqD2OAUeMCzH__9I_wLzzIvU</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Carrara, Greta</creator><creator>Bortoluzzi, Alessandra</creator><creator>Sakellariou, Garifallia</creator><creator>Silvagni, Ettore</creator><creator>Zanetti, Anna</creator><creator>Govoni, Marcello</creator><creator>Scirè, Carlo Alberto</creator><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201901</creationdate><title>Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology</title><author>Carrara, Greta ; Bortoluzzi, Alessandra ; Sakellariou, Garifallia ; Silvagni, Ettore ; Zanetti, Anna ; Govoni, Marcello ; Scirè, Carlo Alberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-9ad1f88e58d0de991e8f2cc0f2533153f7992c721a8a204a02b6b411903b6c1a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carrara, Greta</creatorcontrib><creatorcontrib>Bortoluzzi, Alessandra</creatorcontrib><creatorcontrib>Sakellariou, Garifallia</creatorcontrib><creatorcontrib>Silvagni, Ettore</creatorcontrib><creatorcontrib>Zanetti, Anna</creatorcontrib><creatorcontrib>Govoni, Marcello</creatorcontrib><creatorcontrib>Scirè, Carlo Alberto</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carrara, Greta</au><au>Bortoluzzi, Alessandra</au><au>Sakellariou, Garifallia</au><au>Silvagni, Ettore</au><au>Zanetti, Anna</au><au>Govoni, Marcello</au><au>Scirè, Carlo Alberto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2019-01</date><risdate>2019</risdate><volume>37</volume><issue>1</issue><spage>60</spage><epage>66</epage><pages>60-66</pages><issn>0392-856X</issn><abstract>The aims of this study were to define the risk of serious bacterial infections in patients receiving specific biological disease-modifying anti-rheumatic drugs (bDMARDs) and evaluating the effect of concomitant synthetic DMARDs (sDMARDs) in a large population-based sample of rheumatoid arthritis (RA) deriving from an administrative health database. Data were extracted from health databases of Lombardy Region, Italy (2004-2013), as a part of the RECord-linkage On Rheumatic Diseases (RECORD) study. Patients with RA treated with approved bDMARDs were included. Hospitalisations for bacterial infections were evaluated by hospital discharge forms. The association between drug exposure and infections was assessed by survival models, with time-dependent covariates. Results are presented as hazard ratios (HR) and 95%CI, crude and adjusted for pre-specified confounders (sex, age, disease duration, Charlson Comorbidity Index, previous biologics, previous infections, use of methotrexate, leflunomide, corticosteroids, non-steroidal anti-inflammatory drugs). 4,656 RA patients with at least one bDMARD prescription were included, for a total of 7,601 biological courses; 3,603 (77.4%) women with a mean (SD) age of 55.8 (12.7) years. Crude incidence rate of hospitalised infection ranged from 0.14 to 2.95 per 1000 person-years. After multivariable adjustment, abatacept users (HR 0.29, 95%CI 0.10-0.82) had significantly lower risk of infections compared to etanercept. Concurrent treatment with methotrexate (0.72, 0.52-0.99) reduced the overall risk of infection while glucocorticoids increased it (1.09 per mg/day, 1.06-1.11). In RA patients treated with bDMARDs, abatacept was associated with the lowest risk of infections; overall risk was mitigated by concomitant methotrexate and increased by glucocorticoids in a dose-dependent manner.</abstract><cop>Italy</cop><pmid>30148440</pmid><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0392-856X
ispartof Clinical and experimental rheumatology, 2019-01, Vol.37 (1), p.60-66
issn 0392-856X
language eng
recordid cdi_proquest_miscellaneous_2094422177
source Alma/SFX Local Collection
title Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T00%3A28%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20of%20hospitalisation%20for%20serious%20bacterial%20infections%20in%20patients%20with%20rheumatoid%20arthritis%20treated%20with%20biologics.%20Analysis%20from%20the%20RECord%20linkage%20On%20Rheumatic%20Disease%20study%20of%20the%20Italian%20Society%20for%20Rheumatology&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=Carrara,%20Greta&rft.date=2019-01&rft.volume=37&rft.issue=1&rft.spage=60&rft.epage=66&rft.pages=60-66&rft.issn=0392-856X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2094422177%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2094422177&rft_id=info:pmid/30148440&rfr_iscdi=true